Indoleamine 2,3-Dioxygenase+ Cells Correspond to the BDCA2+ Plasmacytoid Dendritic Cells in Human Melanoma Sentinel Nodes

被引：38

作者：

Gerlini, Gianni ^{[1
]}

Di Gennaro, Paola ^{[2
]}

Mariotti, Giulia ^{[2
]}

Urso, Carmelo ^{[3
]}

Chiarugi, Alberto ^{[4
]}

Pimpinelli, Nicola ^{[2
]}

Borgognoni, Lorenzo ^{[1
]}

机构：

[1] Santa Maria Annunziata Hosp, Tuscan Tumor Inst ITT, Plast Surg Unit, Reg Melanoma Referral Ctr, Florence, Italy

[2] Univ Florence, Sch Med, Dept Dermatol Sci, Florence, Italy

[3] Santa Maria Annunziata Hosp, Dept Anat Pathol, Dermatopathol Sect, Florence, Italy

[4] Univ Florence, Sch Med, Dept Pharmacol, Florence, Italy

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2010年 / 130卷 / 03期

关键词：

INHIBITION;

D O I：

10.1038/jid.2009.307

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：898 / 901

页数：4

共 21 条

[11] Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis [J].

Liu, Hanzhong ;

Liu, Li ;

Fletcher, Bradley S. ;

Visner, Gary A. .

FASEB JOURNAL, 2006, 20 (13) :2384-+

[12] Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity [J].

Liu, YJ .

CELL, 2001, 106 (03) :259-262

[13] Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients [J].

Molenkamp, Barbara G. ;

Sluijter, Berbel J. R. ;

van Leuwen, Paul A. M. ;

Santegoets, Saskia J. A. M. ;

Meijer, Sybren ;

Wijnands, Pepijn G. J. T. B. ;

Haanen, John B. A. G. ;

van den Eertwegh, Alfons J. M. ;

Scheper, Rik J. ;

de Gruijl, Tanja D. .

CLINICAL CANCER RESEARCH, 2008, 14 (14) :4532-4542

[14] Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients [J].

Molenkamp, Barbara G. ;

van Leeuwen, Paul A. M. ;

Meijer, Sybren ;

Sluijter, Berbel J. R. ;

Wijnands, Pepijn G. J. T. B. ;

Baars, Arnold ;

van den Eertwegh, Alfons J. M. ;

Scheper, Rik J. ;

de Grujil, Tanja D. .

CLINICAL CANCER RESEARCH, 2007, 13 (10) :2961-2969

[15] Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy [J].

Muller, AJ ;

DuHadaway, JB ;

Donover, PS ;

Sutanto-Ward, E ;

Prendergast, GC .

NATURE MEDICINE, 2005, 11 (03) :312-319

[16] Indoleamine 2,3-dioxygenase and tumor-induced tolerance [J].

Munn, David H. ;

Mellor, Andrew L. .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) :1147-1154

[17] Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase [J].

Munn, DH ;

Sharma, MD ;

Lee, JR ;

Jhaver, KG ;

Johnson, TS ;

Keskin, DB ;

Marshall, B ;

Chandler, P ;

Antonia, SJ ;

Burgess, R ;

Slingluff, CL ;

Mellor, AL .

SCIENCE, 2002, 297 (5588) :1867-1870

[18] Prevention of allogeneic fetal rejection by tryptophan catabolism [J].

Munn, DH ;

Zhou, M ;

Attwood, JT ;

Bondarev, I ;

Conway, SJ ;

Marshall, B ;

Brown, C ;

Mellor, AL .

SCIENCE, 1998, 281 (5380) :1191-1193

[19] Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes [J].

Munn, DH ;

Sharma, MD ;

Hou, D ;

Baban, B ;

Lee, JR ;

Antonia, SJ ;

Messina, JL ;

Chandler, P ;

Koni, PA ;

Mellor, AL .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (02) :280-290

[20] The nature of the principal type 1 interferon-producing cells in human blood [J].

Siegal, FP ;

Kadowaki, N ;

Shodell, M ;

Fitzgerald-Bocarsly, PA ;

Shah, K ;

Ho, S ;

Antonenko, S ;

Liu, YJ .

SCIENCE, 1999, 284 (5421) :1835-1837

← 1 2 3 →